{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:48:02Z","timestamp":1791110882286,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejso.2022.06.014","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T21:58:14Z","timestamp":1655503094000},"page":"2218-2225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-8343","authenticated-orcid":false,"given":"Michael P.","family":"Flood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8395-7355","authenticated-orcid":false,"given":"Anshini","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5596-9511","authenticated-orcid":false,"given":"Catherine","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-6128","authenticated-orcid":false,"given":"Chelsee","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5003-0433","authenticated-orcid":false,"given":"Robert","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-2662","authenticated-orcid":false,"given":"Michael","family":"Michael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Heriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-2057","authenticated-orcid":false,"given":"Jeanne","family":"Tie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejso.2022.06.014_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.surge.2020.08.016","article-title":"Survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a systematic review and discussion of latest controversies","volume":"19","author":"Flood","year":"2021","journal-title":"Surgeon"},{"issue":"2","key":"10.1016\/j.ejso.2022.06.014_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jso.24290","article-title":"Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort","volume":"114","author":"Froysnes","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2022.06.014_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jso.24248","article-title":"What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures","volume":"113","author":"Passot","year":"2016","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.06.014_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12957-020-1784-4","article-title":"The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"18","author":"Wong","year":"2020","journal-title":"World J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2022.06.014_bib5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/DCR.0000000000000149","article-title":"Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients","volume":"57","author":"Baratti","year":"2014","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"10.1016\/j.ejso.2022.06.014_bib6","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1245\/s10434-019-07294-y","article-title":"Impact of synchronous versus metachronous onset of colorectal peritoneal metastases on survival outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC): a multicenter, retrospective, observational study","volume":"26","author":"Hentzen","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2022.06.014_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/DCR.0000000000001456","article-title":"Evolution of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: 8-year single-institutional experience","volume":"62","author":"Narasimhan","year":"2019","journal-title":"Dis Colon Rectum"},{"issue":"11","key":"10.1016\/j.ejso.2022.06.014_bib8","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/codi.15003","article-title":"Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis","volume":"22","author":"Narasimhan","year":"2020","journal-title":"Colorectal Dis"},{"issue":"1","key":"10.1016\/j.ejso.2022.06.014_bib9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/BF00690419","article-title":"The Ras signal transduction pathway","volume":"13","author":"Khosravi-Far","year":"1994","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"10.1016\/j.ejso.2022.06.014_bib10","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2022.06.014_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","article-title":"Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer","volume":"33","author":"Van Cutsem","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2022.06.014_bib12","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/bjc.2014.499","article-title":"KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer","volume":"112","author":"Renaud","year":"2015","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2022.06.014_bib13","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/SLA.0b013e3182a5025a","article-title":"RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases","volume":"258","author":"Vauthey","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2022.06.014_bib14","article-title":"Microsatellite and RAS\/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)","author":"Tonello","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"23","key":"10.1016\/j.ejso.2022.06.014_bib15","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2022.06.014_bib16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jamaoncol.2016.5469","article-title":"Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers : a secondary analysis of 2 randomized clinical trials","volume":"3","author":"Sinicrope","year":"2017","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2022.06.014_bib17","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejso.2022.06.014_bib18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ejso.2022.06.014_bib19","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1200\/JCO.2016.71.4394","article-title":"(Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","volume":"35","author":"Jones","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2022.06.014_bib20","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1245\/s10434-020-09161-7","article-title":"Prognostic impact of primary side and RAS\/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases","volume":"28","author":"Baratti","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.06.014_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","article-title":"Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC","volume":"27","author":"Graf","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2022.06.014_bib22","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.ejso.2021.05.023","article-title":"The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: a web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)","volume":"47","author":"van de Vlasakker","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"20","key":"10.1016\/j.ejso.2022.06.014_bib23","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejso.2022.06.014_bib24","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1245\/s10434-021-10289-3","article-title":"Definition and prediction of early recurrence and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: towards predicting oncologic futility preoperatively","volume":"28","author":"Rieser","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"17","key":"10.1016\/j.ejso.2022.06.014_bib25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600e-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2022.06.014_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600e-mutant metastatic colorectal cancer: updated survival results and subgroup Analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ejso.2022.06.014_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.4_suppl.012","article-title":"Phase I\/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer","volume":"40","author":"Morris","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.06.014_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamasurg.2021.5679","article-title":"Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma","volume":"157","author":"Zhou","year":"2022","journal-title":"JAMA Surg"},{"issue":"2","key":"10.1016\/j.ejso.2022.06.014_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2030638","article-title":"Distribution of KRAS (G12C) somatic mutations across race, sex, and cancer type","volume":"384","author":"Nassar","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2022.06.014_bib30","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.06.014_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdu499","article-title":"Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial","volume":"26","author":"Klingbiel","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2022.06.014_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/jso.23755","article-title":"Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer","volume":"110","author":"Ooki","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2022.06.014_bib33","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-2581","article-title":"Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy\u00a0+\/- cetuximab","volume":"19","author":"Smith","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2022.06.014_bib34","article-title":"Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients","author":"Larsen","year":"2021","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2022.06.014_bib35","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ejso.2022.06.014_bib36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","article-title":"Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition","volume":"9","author":"Fabrizio","year":"2018","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2022.06.014_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2022.06.014_bib38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3892\/or.2016.5323","article-title":"High concordance rate of KRAS\/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases","volume":"37","author":"Fujiyoshi","year":"2017","journal-title":"Oncol Rep"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832200498X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832200498X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:44:37Z","timestamp":1760060677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832200498X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S074879832200498X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2022.06.014","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2022.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}